Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRX NASDAQ:KRRO NASDAQ:NLTX NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.36+1.7%$5.30$2.20▼$6.20$189.50M1.57,734 shs16,816 shsKRROKorro Bio$23.08-2.5%$15.74$10.29▼$98.00$222.28M2.51137,119 shs189,912 shsNLTXNeoleukin Therapeutics$18.84-4.3%$20.39$2.03▼$14.36$177.06M1.1150,104 shs86,287 shsTELOTelomir Pharmaceuticals$1.32-10.8%$1.58$1.12▼$8.40$47.78M-0.674.08 million shs2.68 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals+1.71%+1.52%+1.32%+36.39%+104.58%KRROKorro Bio-2.49%+15.17%+41.94%+100.35%-53.82%NLTXNeoleukin Therapeutics-4.34%-4.61%-13.10%+10.76%-47.30%TELOTelomir Pharmaceuticals-10.81%-8.97%-32.65%-32.31%-74.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPRXEupraxia Pharmaceuticals2.2432 of 5 stars3.61.00.00.02.60.00.6KRROKorro Bio1.4634 of 5 stars3.61.00.00.02.60.00.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATELOTelomir Pharmaceuticals2.5401 of 5 stars3.82.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 3.17Buy$11.00105.22% UpsideKRROKorro Bio 3.29Buy$86.83276.23% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ATELOTelomir Pharmaceuticals 3.50Strong Buy$15.001,036.36% UpsideCurrent Analyst Ratings BreakdownLatest TELO, KRRO, EPRX, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.008/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.008/13/2025KRROKorro BioRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetStrong-Buy ➝ Strong-Buy$153.00 ➝ $147.008/13/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$100.00 ➝ $90.007/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$11.007/24/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSpeculative Buy(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/A($0.30) per shareN/AKRROKorro Bio$2.27M95.47N/AN/A$12.26 per share1.88NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$25.50M-$0.85N/AN/AN/AN/A-367.73%-126.38%11/6/2025 (Estimated)KRROKorro Bio-$83.58M-$9.75N/AN/AN/AN/A-61.51%-42.87%11/11/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ATELOTelomir Pharmaceuticals-$16.53M-$0.54N/AN/AN/AN/A-4,595.08%-1,750.91%11/11/2025 (Estimated)Latest TELO, KRRO, EPRX, and NLTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025TELOTelomir Pharmaceuticals-$0.08-$0.17-$0.09-$0.17N/AN/A8/12/2025Q2 2025EPRXEupraxia Pharmaceuticals-$0.21-$0.26-$0.05-$0.26N/AN/A8/12/2025Q2 2025KRROKorro Bio-$2.54-$2.74-$0.20-$2.74$0.41 million$1.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A8.728.72KRROKorro BioN/A5.985.98NLTXNeoleukin TherapeuticsN/A15.3315.33TELOTelomir PharmaceuticalsN/A2.392.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AKRROKorro Bio13.18%NLTXNeoleukin Therapeutics52.37%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AKRROKorro Bio4.60%NLTXNeoleukin Therapeutics1.58%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AKRROKorro Bio709.39 million8.96 millionNo DataNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataTELOTelomir Pharmaceuticals132.28 millionN/AN/ATELO, KRRO, EPRX, and NLTX HeadlinesRecent News About These CompaniesTelomir stock soars after drug candidate shows promising epigenetic effectsAugust 28 at 1:23 PM | za.investing.comTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...August 28 at 1:23 PM | kansascity.comKTelomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related DiseasesAugust 28 at 8:00 AM | accessnewswire.comATELO Makes Progress Toward Human TrialsAugust 15, 2025 | msn.comTelomir-1 inhibits key histone demethylase enzymes in vitroAugust 12, 2025 | bioworld.comBTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...August 8, 2025 | kansascity.comKTelomir Flat on Trial Data ReleaseAugust 7, 2025 | baystreet.caTelomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic DysfunctionAugust 7, 2025 | accessnewswire.comATelomir Pharmaceuticals (TELO) Expected to Announce Earnings on TuesdayAugust 6, 2025 | marketbeat.comTelomir Pharmaceuticals Announces Promising Preclinical ResultsJuly 26, 2025 | theglobeandmail.comTelomir Pharmaceuticals stock surges on promising Progeria treatment resultsJuly 25, 2025 | investing.comTELO Announces Another Important BreakthroughJuly 25, 2025 | finance.yahoo.comTelomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson'sJuly 24, 2025 | accessnewswire.comATelomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer ResultsJuly 18, 2025 | msn.comTelomir Pharmaceuticals stock soars after promising cancer treatment dataJuly 18, 2025 | investing.comTelomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger GainsJuly 18, 2025 | msn.comTelomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and RapamycinJuly 18, 2025 | accessnewswire.comATelomir says data show Telomir-1 reversed epigenetic silencingJuly 17, 2025 | msn.comTelomir Pharmaceuticals Reveals Promising Preclinical Cancer ResultsJuly 17, 2025 | tipranks.comTelomir Pharmaceuticals Inc News (TELO) - Investing.comJuly 1, 2025 | investing.comTelomir Pharmaceuticals Reports Positive Preclinical DataJune 18, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTELO, KRRO, EPRX, and NLTX Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$5.36 +0.09 (+1.71%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.54 +0.18 (+3.26%) As of 08/29/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.Korro Bio NASDAQ:KRRO$23.08 -0.59 (-2.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$23.06 -0.02 (-0.11%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Neoleukin Therapeutics NASDAQ:NLTX$18.84 -0.86 (-4.34%) As of 08/28/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Telomir Pharmaceuticals NASDAQ:TELO$1.32 -0.16 (-10.81%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.32 -0.01 (-0.38%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
